BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27496425)

  • 1. Human Pooled Immunoglobulin as Treatment of Active Antibody-Mediated Rejection of Transplanted Kidney.
    Furmańczyk-Zawiska A; Urbanowicz A; Perkowska-Ptasińska A; Bączkowska T; Sadowska A; Nazarewski S; Chmura A; Durlik M
    Transplant Proc; 2016 Jun; 48(5):1446-50. PubMed ID: 27496425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
    Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
    Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
    Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C
    J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
    Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
    Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.
    Kikić Ž; Kainz A; Kozakowski N; Oberbauer R; Regele H; Bond G; Böhmig GA
    Clin J Am Soc Nephrol; 2015 Aug; 10(8):1435-43. PubMed ID: 26071493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis and Treatment for Active and Chronic Antibody-Mediated Rejection in Renal Transplant Recipients; Single Center Experience.
    Yilmaz VT; Dandin O; Kisaoglu A; Avanaz A; Kamaci D; Toru HS; Demiryilmaz I; Koksoy S; Aydinli B; Kocak H
    Transplant Proc; 2022 Sep; 54(7):1809-1815. PubMed ID: 35907695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.
    Lachmann N; Duerr M; Schönemann C; Pruß A; Budde K; Waiser J
    J Immunol Res; 2017; 2017():6872046. PubMed ID: 28255562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
    Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
    BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection.
    Sablik KA; Clahsen-van Groningen MC; Looman CWN; Damman J; van Agteren M; Betjes MGH
    BMC Nephrol; 2019 Jun; 20(1):218. PubMed ID: 31200654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.
    Matignon M; Pilon C; Commereuc M; Grondin C; Leibler C; Kofman T; Audard V; Cohen J; Canoui-Poitrine F; Grimbert P
    PLoS One; 2017; 12(6):e0178572. PubMed ID: 28654684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
    Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
    J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
    Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
    J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.